<DOC>
	<DOCNO>NCT01388855</DOCNO>
	<brief_summary>The purpose study determine method feasible large clinical trial.The study examine relationship vitamin D status , quality life , pain walk distance individual live heart failure .</brief_summary>
	<brief_title>Pilot Study Vitamin D Supplementation Heart Failure</brief_title>
	<detailed_description>This study conduct pilot project determine feasibility method inform conduct future large study . This double-blind randomized control trial examine relationship vitamin D status , Quality Life ( QOL ) , pain functional capacity individual live heart failure ( HF ) pre post vitamin D supplementation . The study outcome measure include : rate recruitment , retention compliance study procedure . Quality life measure EQ-5D™ questionnaire ; Brief Pain Inventory ( BPI ) use evaluate subject pain . The 6-minute walk test ( 6MWT ) evaluate functional capacity . Serum 25-hydroxyvitamin D ( 25OHD ) level quantify adequacy vitamin D dose achieve target 25OHD level . A convenience sample 40 subject ( 20 per treatment group ) prospectively recruit Royal Columbian Hospital ( RCH ) Heart Function ( HFx ) Clinic . Subjects randomize receive either vitamin D3 ( cholecalciferol ) match placebo dose 20,000 IU daily 30 day follow 20,000 IU weekly 8 week . Subjects 25OHD level measure , self-administer EQ-5D™ BPI questionnaires perform 6MWT study entry completion study ( 12 week entry ) . Descriptive statistic ( mean , standard deviation proportion appropriate ) use describe data . The feasibility study procedure report percentage compare standard set team 80 % .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>65 year age old New York Heart Association functional Class II III symptom Ability communicate English translator Competent sign inform consent Comorbidity would negatively impact quality life ( e.g . severe arthritis , fibromyalgia ) Comorbidity would negatively impact vitamin D metabolism ( glomerular filtration rate1529 % , significant liver dysfunction On pharmaceutical agent could lower Vitamin D level ( e.g . glucocorticoid , anticonvulsant ) Taking &gt; 600 IU vitamin D ( cholecalciferol ergocalciferol ) daily Moderate severe cognitive impairment Contraindication vitamin D supplementation : history hypercalcemia condition increase risk hypercalcemia ( sarcoidosis , tuberculosis lymphoma ) Wheelchair bound ( ambulation component QOL questionnaire</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Pain</keyword>
	<keyword>Pilot Study</keyword>
	<keyword>RCT</keyword>
</DOC>